Back to Search
Start Over
Defect engineering synergistically boosts the catalytic activity of Fe-MoO v for highly efficient breast mesh antitumor therapy.
- Source :
-
Journal of colloid and interface science [J Colloid Interface Sci] 2025 Jan 15; Vol. 678 (Pt A), pp. 260-271. Date of Electronic Publication: 2024 Aug 25. - Publication Year :
- 2025
-
Abstract
- The demand for breast mesh with antitumor properties is critical in post-mastectomy breast reconstruction to prevent local tumor recurrence. Molybdenum-based oxide (MoO <subscript>x</subscript> ) exhibits enzyme-like activities by catalyzing endogenous hydrogen peroxide to produce reactive oxygen species for inducing tumor cell apoptosis. However, its catalytic activity is limited by insufficient active sites. Herein, a defect engineering strategy is proposed to create redox nanozymes with multiple enzymatic activities by incorporating Fe into MoO <subscript>x</subscript> (Fe-MoO <subscript>v</subscript> ). Fe-MoO <subscript>v</subscript> is subsequently integrated into polycaprolactone (PCL) to fabricate breast meshes for establishing an enzyme-catalyzed antitumor platform. The doping of Fe into MoO <subscript>x</subscript> formed numerous defect sites, including oxygen vacancies (OV) and Fe substitution sites, synergistically boosting the binding capacity and catalytic activity of Fe-MoO <subscript>v</subscript> . Density functional theory calculations demonstrated that the outstanding peroxidase-like catalytic activity of Fe-MoO <subscript>v</subscript> resulted from the synergy between OV and Fe sites. Additionally, OV contributes to the localized surface plasmon resonance effect, enhancing the photothermal capability of the PCL/Fe-MoO <subscript>v</subscript> mesh. Upon near-infrared laser exposure, the catalytic activity of the PCL/Fe-MoO <subscript>v</subscript> mesh is further improved, leading to increased generation of reactive oxygen species and enhanced antitumor efficacy, achieving 86.7% tumor cell mortality, a 264% enhancement compared to the PCL/MoO <subscript>x</subscript> mesh.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Published by Elsevier Inc.)
- Subjects :
- Humans
Catalysis
Iron chemistry
Iron metabolism
Breast Neoplasms pathology
Reactive Oxygen Species metabolism
Female
Drug Screening Assays, Antitumor
Mice
Polyesters chemistry
Animals
Cell Proliferation drug effects
Surface Properties
Particle Size
Surgical Mesh
Density Functional Theory
Apoptosis drug effects
Molybdenum chemistry
Antineoplastic Agents chemistry
Antineoplastic Agents pharmacology
Oxides chemistry
Oxides pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1095-7103
- Volume :
- 678
- Issue :
- Pt A
- Database :
- MEDLINE
- Journal :
- Journal of colloid and interface science
- Publication Type :
- Academic Journal
- Accession number :
- 39197369
- Full Text :
- https://doi.org/10.1016/j.jcis.2024.08.195